• Target：
• AChRα1

• Fields：
• >>Neuroactive ligand-receptor interaction

• Gene Name：
• CHRNA1

• Protein Name：
• Acetylcholine receptor subunit alpha

• Human Gene Id：
• 1134

• Human Swiss Prot No：
• P02708

• Mouse Gene Id：
• 11435

• Mouse Swiss Prot No：
• P04756

• Rat Gene Id：
• 79557

• Rat Swiss Prot No：
• P25108

• Immunogen：
• The antiserum was produced against synthesized peptide derived from the Internal region of human CHRNA1. AA range:171-220

• Specificity：
• AChRα1 Polyclonal Antibody detects endogenous levels of AChRα1 protein.

• Formulation：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• Source：
• Polyclonal, Rabbit,IgG

• Dilution：
• WB 1:500 - 1:2000. ELISA: 1:5000. IF 1:100-300 Not yet tested in other applications.

• Purification：
• The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

• Concentration：
• 1 mg/ml

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• CHRNA1;ACHRA;CHNRA;Acetylcholine receptor subunit alpha

• Observed Band(KD)：
• 55kD

• Background：
• The muscle acetylcholine receptor consiststs of 5 subunits of 4 different types: 2 alpha subunits and 1 each of the beta, gamma, and delta subunits. This gene encodes an alpha subunit that plays a role in acetlycholine binding/channel gating. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Nov 2012],

• Function：
• disease:Defects in CHRNA1 are a cause of congenital myasthenic syndrome fast-channel type (FCCMS) [MIM:608930]. FCCMS is a congenital myasthenic syndrome characterized by kinetic abnormalities of the AChR. In most cases, FCCMS is due to mutations that decrease activity of the AChR by slowing the rate of opening of the receptor channel, speeding the rate of closure of the channel, or decreasing the number of openings of the channel during ACh occupancy. The result is failure to achieve threshold depolarization of the endplate and consequent failure to fire an action potential.,disease:Defects in CHRNA1 are a cause of congenital myasthenic syndrome slow-channel type (SCCMS) [MIM:601462]. SCCMS is the most common congenital myasthenic syndrome. Congenital myasthenic syndromes are characterized by muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the

• Subcellular Location：
• Cell junction, synapse, postsynaptic cell membrane ; Multi-pass membrane protein . Cell membrane ; Multi-pass membrane protein .

• Expression：
• Isoform 1 is only expressed in skeletal muscle. Isoform 2 is constitutively expressed in skeletal muscle, brain, heart, kidney, liver, lung and thymus.

Autoimmune regulator expression in thymomas with or without autoimmune disease. IMMUNOLOGY LETTERS 2014 Apr 21 IHC Human 1:50 thymoma tissues

SCF/C-KIT signaling modulates tryptase expression in acute myeloid leukemia cells. INTERNATIONAL JOURNAL OF HEMATOLOGY Int J Hematol. 2014 Jun;99(6):750-757 WB Human U937 cell

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs